Clinical Trial: Durability of Three Monthly Loading Doses With Faricimab in Treatment-naïve Neovascular Age-related Macular Degeneration
Study Status: COMPLETED
Recruit Status: COMPLETED
Condition: Neovascular Age-Related Macular Degeneration (nAMD)
Study Type: OBSERVATIONAL
Official Title: Durability of Three Monthly Loading Doses With Faricimab Injections in Patients With Treatment-naïve Neovascular Age-related Macular Degeneration
Brief Summary:
Neovascular Age-Related Macular Degeneration (nAMD) is a one of the leading causes of irreversible vision loss among the elderly in developed countries.The implementation of anti-VEGF therapies in the last decades has significantly improved AMD management.Faricimab (Vabysmo®), a bispecific antibody targeting both Vascular Endothelial Growth Factor A (VEGF-A) and Angiopoietin-2 (Ang-2), offers enhanced disease control by both inhibiting angiogenesis and stabilizing blood vessels to prevent inflammation and…
Read more